atomoxetine hydrochloride has been researched along with Cognition Disorders in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alkam, T; Aoyama, Y; Hiramatsu, M; Kihara, D; Kim, HC; Kimura, N; Mamiya, T; Nabeshima, T; Tsunoda, Y; Yoshida, A | 1 |
| Clarke, S; Efron, D; Griffiths, KR; Hermens, DF; Kohn, MR; Leikauf, JE; Tsang, TW; Williams, LM | 1 |
| Altena, E; Barker, RA; Housden, CR; Huddleston, C; Maxwell, H; Nombela, C; Rae, CL; Regenthal, R; Rittman, T; Robbins, TW; Rowe, JB; Sahakian, BJ; Ye, Z | 1 |
| Li, R; Yang, R | 1 |
| Ago, Y; Baba, A; Hashimoto, H; Hashimoto, R; Hayata-Takano, A; Hazama, K; Kasai, A; Katayama, T; Köves, K; Matsuda, T; Matsuzaki, S; Nagayasu, K; Nakazawa, T; Onaka, Y; Reglődi, D; Shibasaki, Y; Shintani, N; Tamas, A; Tanida, M; Taniike, M; Waschek, JA; Yamada, K | 1 |
| Agrawal, N; Dougall, D; Poole, N | 1 |
| Jepson, C; Lerman, C; Lynch, K; Patterson, F; Ray, R; Rukstalis, M; Strasser, A | 1 |
| Allen, BD; Balci, F; Brunner, D; Fedolak, TE; Frank, KM; Gibson, JM; Kapustinski, BJ; Ludvig, EA | 1 |
| Creeden, C; George, TP; Reutenauer, EL; Sacco, KA; Vessicchio, JC; Weinberger, AH | 1 |
| Biglan, K; Gerstenhaber, M; Marsh, L; Williams, JR | 1 |
| Ball, MP; Boggs, DL; Buchanan, RW; Conley, RR; Dickinson, D; Feldman, S; Gold, JM; Kelly, DL; Liu, F; McMahon, RP; Nelson, M | 1 |
| Baker, KD; Feldman, PD; Mohs, RC; Porsteinsson, AP; Shiovitz, TM; Tariot, PN | 1 |
| Adams, WH; Beglinger, LJ; Duff, K; Fiedorowicz, JG; Langbehn, DR; Leserman, A; Paulsen, JS; Paulson, H | 1 |
| Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D | 1 |
| Fernández-Jaén, A; Martín Fernández-Mayoralas, D | 1 |
| Arneric, SP; Bain, JN; Buccafusco, JJ; Prendergast, MA; Smith, MA; Terry, AV | 1 |
| Friedman, JI; Gorman, JM; Stewart, DG | 1 |
| Kashani, J; Lovecchio, F | 1 |
| Gangadhar, BN; Rao, NP; Venkatasubramanian, G | 1 |
| Bowler, S; Carpenter, D; Elbaz, Z; Fan, J; Flanagan, L; Friedman, JI; Harvey, PD; Lu, J; Parrella, M; Tang, CY; White, L | 1 |
| Hamm, RJ; Reid, WM | 1 |
3 review(s) available for atomoxetine hydrochloride and Cognition Disorders
| Article | Year |
|---|---|
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Benzhydryl Compounds; Brain Injuries; Chronic Disease; Cognition; Cognition Disorders; Humans; Middle Aged; Modafinil; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2015 |
[Alcoholic foetopathy: an update].
Topics: Adrenergic Uptake Inhibitors; Alcoholism; Atomoxetine Hydrochloride; Central Nervous System Stimulants; Cognition Disorders; Diagnosis, Differential; Female; Fetal Alcohol Spectrum Disorders; Humans; Methylphenidate; Nervous System Malformations; Pregnancy; Propylamines; Randomized Controlled Trials as Topic | 2011 |
Potential noradrenergic targets for cognitive enhancement in schizophrenia.
Topics: Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Cognition Disorders; Guanfacine; Humans; Norepinephrine; Prefrontal Cortex; Propylamines; Schizophrenia | 2004 |
9 trial(s) available for atomoxetine hydrochloride and Cognition Disorders
| Article | Year |
|---|---|
Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition Disorders; Cohort Studies; Cross-Over Studies; Double-Blind Method; Female; Humans; Inhibition, Psychological; Male; Psychiatric Status Rating Scales; Treatment Outcome | 2018 |
Improving response inhibition in Parkinson's disease with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Atomoxetine Hydrochloride; Brain; Choice Behavior; Cognition Disorders; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Inhibition, Psychological; Male; Middle Aged; Neural Pathways; Neuropsychological Tests; Oxygen; Parkinson Disease; Reaction Time | 2015 |
Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Cognition Disorders; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Norepinephrine; Prefrontal Cortex; Propylamines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Cessation | 2009 |
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antiparkinson Agents; Atomoxetine Hydrochloride; Bipolar Disorder; Cognition Disorders; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Nootropic Agents; Parkinson Disease; Pilot Projects; Prefrontal Cortex; Propylamines; Psychological Tests; Psychotropic Drugs; Severity of Illness Index; Treatment Outcome | 2009 |
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Brief Psychiatric Rating Scale; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Propylamines; Schizophrenia; Severity of Illness Index | 2009 |
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Alzheimer Disease; Atomoxetine Hydrochloride; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Propylamines; Treatment Outcome | 2009 |
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease.
Topics: Adult; Atomoxetine Hydrochloride; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Pilot Projects; Propylamines; Time Factors; Young Adult | 2009 |
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Cognition Disorders; Comorbidity; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2010 |
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Cognition Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Pilot Projects; Propylamines; Schizophrenia; Schizophrenic Psychology | 2008 |
9 other study(ies) available for atomoxetine hydrochloride and Cognition Disorders
| Article | Year |
|---|---|
Prenatal nicotine exposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognition Disorders; Dopamine; Female; Male; Mice; Mice, Inbred C57BL; Nicotine; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects | 2017 |
Could atomoxetine improve sluggish cognitive tempo symptoms?
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Cognition Disorders; Humans; Nootropic Agents; Propylamines | 2014 |
Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atomoxetine Hydrochloride; Biogenic Monoamines; Cognition Disorders; Dose-Response Relationship, Drug; Exploratory Behavior; Hyperkinesis; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Pituitary Adenylate Cyclase-Activating Polypeptide; Prepulse Inhibition; Recognition, Psychology | 2015 |
Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Cognition; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Propylamines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome | 2009 |
Pharmacological manipulations of interval timing using the peak procedure in male C3H mice.
Topics: Animals; Atomoxetine Hydrochloride; Behavior, Animal; Chlordiazepoxide; Cognition; Cognition Disorders; Conditioning, Operant; Dextroamphetamine; Dopamine Agonists; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Methamphetamine; Mice; Mice, Inbred C3H; Nootropic Agents; Physostigmine; Propylamines; Psychophysiology; Reaction Time; Scopolamine; Sodium Chloride; Statistics as Topic; Time Factors; Time Perception | 2008 |
Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential.
Topics: Animals; Atomoxetine Hydrochloride; Attention; Caffeine; Cognition; Cognition Disorders; Color Perception; Female; Macaca mulatta; Macaca nemestrina; Male; Methylphenidate; Morphine; Neuropsychological Tests; Nicotine; Nomifensine; Photic Stimulation; Propylamines; Substance-Related Disorders; Task Performance and Analysis | 2003 |
Isolated atomoxetine (Strattera) ingestions commonly result in toxicity.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cognition Disorders; Drug Overdose; Humans; Infant; Poison Control Centers; Propylamines; Retrospective Studies; Tachycardia; Vomiting | 2006 |
Treatment of cognitive deficits in schizophrenia with atomoxetine: a case report.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Cognition Disorders; Female; Humans; Propylamines; Schizophrenia; Treatment Outcome | 2007 |
Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Brain Injuries; Catecholamines; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Maze Learning; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Rats; Rats, Sprague-Dawley; Recovery of Function; Time Factors; Treatment Outcome | 2008 |